RAPT Therapeutics, Inc.

NASDAQ:RAPT

0.91 (USD) • At close April 29, 2025
Bedrijfsnaam RAPT Therapeutics, Inc.
Symbool RAPT
Munteenheid USD
Prijs 0.906
Beurswaarde 119,598,342
Dividendpercentage 0%
52-weken bereik 0.753 - 8.58
Industrie Biotechnology
Sector Healthcare
CEO Dr. Brian Russell Wong M.D., Ph.D.
Website https://www.rapt.com

An error occurred while fetching data.

Over RAPT Therapeutics, Inc.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type

Vergelijkbare Aandelen

IRadimed Corporation logo

IRadimed Corporation

IRMD

53.7 USD

Nuvalent, Inc. logo

Nuvalent, Inc.

NUVL

75.87 USD

Kinnate Biopharma Inc. logo

Kinnate Biopharma Inc.

KNTE

2.65 USD

Vaxart, Inc. logo

Vaxart, Inc.

VXRT

0.425 USD

Leafly Holdings, Inc. logo

Leafly Holdings, Inc.

LFLY

0.178 USD

Adicet Bio, Inc. logo

Adicet Bio, Inc.

ACET

0.622 USD

Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc.

PRAX

37.2 USD

Centessa Pharmaceuticals plc logo

Centessa Pharmaceuticals plc

CNTA

13.72 USD

Rallybio Corporation logo

Rallybio Corporation

RLYB

0.304 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)